Program
BMN 351
A development code.
Its studies are mostly in Muscular Dystrophy, Duchenne, led by BioMarin Pharmaceutical.
Furthest: phase 2, since Jan 26, 20242 company-led studies, 2 open or runningNext primary completion: Apr 14, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| BioMarin Pharmaceutical | 22 open or running | phase 2since Jan 26, 2024 | Jan 26, 2024 | Apr 14, 2027phase 2 · NCT06280209 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 26, 2024First study: phase 2 study in Muscular Dystrophy, DuchenneFirst studyNCT06280209 · 18 enrolled · Italy, Netherlands, Spain and more
- Apr 17, 2026Phase 2 study in Muscular Dystrophy, DuchenneNCT07573631 · 18 planned · Italy, Netherlands, Spain and more
Ahead
- Apr 14, 2027Primary completion: phase 2 study in Muscular Dystrophy, DuchenneNCT06280209
- Dec 2031Primary completion: phase 2 study in Muscular Dystrophy, DuchenneNCT07573631
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07573631Muscular Dystrophy, Duchenne · Italy, Netherlands, Spain and more | 2 | By invitation | Dec 2031 | 18 |
| NCT06280209Muscular Dystrophy, Duchenne · Italy, Netherlands, Spain and more | 2 | Active, not recruiting | Apr 14, 2027 | 18 |
How it is read
Names in the registry
- “BMN 351”, 2 entries
Codes read as this program: BMN351.
Conditions, from the studies’ own filings
- Muscular Dystrophy, Duchenne, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.